Literature DB >> 20803079

Sentinel node biopsy in squamous-cell carcinoma of the anal canal.

Paola De Nardi1, Michele Carvello, Carla Canevari, Paolo Passoni, Carlo Staudacher.   

Abstract

BACKGROUND: Radiochemotherapy is the standard treatment for patients with carcinoma of the anal canal. Therefore, a surgical specimen is not usually obtained. Inguinal lymph node metastases cannot be accurately predicted by either clinical examination or imaging techniques. In this study, we applied the sentinel node technique in patients with anal canal squamous-cell carcinoma to determine whether this provided more reliable staging of tumors.
METHODS: From May 2007 to May 2009, we enrolled 11 patients (7 women) with a mean age 65 (range 39-80) years with squamous-cell carcinoma of the anal canal and clinically and radiologically negative groin lymph nodes. The patients were staged with endorectal ultrasound, computed tomographic scan, magnetic resonance imaging of the pelvis, and positron emission tomography. There were two T1, four T2, and five T3 tumors (International Union Against Cancer classification). Lymphoscintigraphy with peritumoral 99mTc colloid injection was performed 16 to 18 h before surgery. During the surgery, patent blue dye was injected peritumorally, and the sentinel inguinal node was identified by a handheld gamma probe and dye visualization.
RESULTS: The sentinel lymph node was detected in all 11 patients by scintigraphy; in 9 cases, the lymph node was in the inguinal region. All of these patients underwent radioguided node biopsy, and a total of 12 lymph nodes were removed. The average diameter of the resected nodes was 8 (range 4-20) mm. No serious complications occurred. In three patients, metastases were identified in the lymph node.
CONCLUSIONS: Sentinel node biopsy is a more accurate method than clinical or radiological techniques to stage the disease of patients with anal carcinoma.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20803079     DOI: 10.1245/s10434-010-1275-x

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  7 in total

Review 1.  So Now My Patient Has Squamous Cell Cancer: Diagnosis, Staging, and Treatment of Squamous Cell Carcinoma of the Anal Canal and Anal Margin.

Authors:  Cindy Kin
Journal:  Clin Colon Rectal Surg       Date:  2018-11-02

Review 2.  New approach to anal cancer: individualized therapy based on sentinel lymph node biopsy.

Authors:  Paola De Nardi; Michele Carvello; Carlo Staudacher
Journal:  World J Gastroenterol       Date:  2012-11-28       Impact factor: 5.742

3.  Anal cancer - a review.

Authors:  Sajad Ahmad Salati; Azzam Al Kadi
Journal:  Int J Health Sci (Qassim)       Date:  2012-06

4.  Perianal mass.

Authors:  Neilendu Kundu; William Abouhassan; Christopher Ibikunle
Journal:  Eplasty       Date:  2011-04-11

Review 5.  Diagnostic performance of positron emission tomography/computed tomography using fluorine-18 fluorodeoxyglucose in detecting locoregional nodal involvement in patients with anal canal cancer: a systematic review and meta-analysis.

Authors:  Carmelo Caldarella; Salvatore Annunziata; Giorgio Treglia; Ramin Sadeghi; Narjes Ayati; Luca Giovanella
Journal:  ScientificWorldJournal       Date:  2014-02-04

6.  Impact of sentinel lymph-node biopsy and FDG-PET in staging and radiation treatment of anal cancer patients.

Authors:  Najla Slim; Paolo Passoni; Elena Incerti; Roberta Tummineri; Calogero Gumina; Giovanni Mauro Cattaneo; Paola De Nardi; Carla Canevari; Claudio Fiorino; Monica Ronzoni; Andrea Marco Tamburini; Valentina Burgio; Luigi Gianolli; Nadia Di Muzio
Journal:  Sci Rep       Date:  2020-09-03       Impact factor: 4.379

7.  Value of staging squamous cell carcinoma of the anal margin and canal using the sentinel lymph node procedure: an update of the series and a review of the literature.

Authors:  D M Mistrangelo; M Bellò; P Cassoni; E Milanesi; P Racca; F Munoz; G Fora; N Rondi; N Gilbo; R Senetta; U Ricardi; M Morino
Journal:  Br J Cancer       Date:  2013-01-17       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.